OPKO Health, Inc.
OPK · NASDAQ
Analyst ratings
buy · 2 ratings
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| March 2, 2026 | Barrington Research | Maintains | Outperform | $1.50 |
| October 31, 2025 | Jefferies | Downgrades | Hold | $1.60 |
| October 30, 2025 | Barrington Research | Maintains | Outperform | $2.25 |
Valuation: Deeply undervalued opportunity vs. overvalued relative to fundamentals
The analyst consensus price target of $3.40 sits more than double the recent share price of $1.53, framing OPKO Health as materially discounted. H.C. Wainwright maintains a Buy rating with a $3.00 price target, and some analysts see fair value as high as $8.50, suggesting significant upside potential.
InvestingPro data indicates the stock is overvalued relative to its Fair Value, with the RSI pointing to overbought territory. At a P/S of 2x, OPKO trades richer than the US Healthcare industry (1.4x) and peers (1.6x), leaving little room for error if revenue or margins disappoint.
Revenue trajectory and path to profitability amid persistent losses
OPKO Health reported annual revenue growth of 3.5% and analysts forecast a 5-year revenue growth rate of 3.81%. Technical indicators show buy signals from both short- and long-term moving averages, and the stock hit a 52-week high with a nearly 20% YTD return, suggesting improving investor confidence.
Q1 2026 revenue of $124.2 million marked a 17.2% year-over-year decline and fell short of H.C. Wainwright's $131.5 million projection. Zacks Research cut its Q2 2028 EPS estimate and maintains a full-year loss forecast of -$0.29 per share, reflecting a deeply challenged profitability outlook.
Analyst sentiment: Buy-rated growth story vs. cautious reduce consensus
StockAnalysis reports a consensus Buy rating from four analysts with an average price target of $2.75, representing 100% upside from recent prices. H.C. Wainwright reiterated its Buy rating even after the Q1 2026 revenue miss, signaling conviction in OPKO's long-term pipeline and strategic positioning.
MarketBeat reports an average rating of 'Reduce' with a consensus target of just $1.55. Barrington Research downgraded OPKO from Outperform to Market Perform, and OPKO's Altman Z-Score of -0.55 and Piotroski F-Score of 2 indicate elevated financial distress and bankruptcy risk.